Cookies on this website
We use cookies to ensure that we give you the best experience on our website. If you click 'Continue' we'll assume that you are happy to receive all cookies and you won't see this message again. Click 'Find out more' for information on how to change your cookie settings.

Three projects from MSD were amongst 10 from across the University to receive funding from the second round of the Public Engagement with Research Seed Fund.

Dr Marco J. Haenssgen, based in the Centre for Tropical Medicine & Global Health, part of the Nuffield Department of Medicine, received funding  to evaluate the process and impact of health-themed science theatre as part of ongoing public engagement activities at the Mahidol Oxford Tropical Medicine Research Unit (MORU). In order to engage the public with its research, MORU is collaborating with B-floor Theatre to produce a performance entitled Fishy Clouds, which explores antimicrobial resistance through puppet plays for both children and adults in Thailand. The social outcomes of drama performances are difficult to evaluate and little guidance exists in the evaluation research literature. This project will test out methods for evaluation, and in doing so inform the theory and practice of evaluating such engagement activities for others.

Simon Knight, based at the Oxford Transplant Centre, part of the Nuffield Department of Surgical Sciences, was awarded funding to develop an online patient advisory panel for renal and transplant research in Oxford, which will provide a patient perspective on upcoming research projects and patient materials.

Dr Marta Valente Pinto, part of the Department of Paediatrics, where she studies pertussis diseases / whooping cough, a highly contagious respiratory infection that, although to some extent preventable by vaccines, continues to be a significant burden around the world. Her project will involve the creation and delivery of workshops in Thames Valley Primary and Secondary Schools to help children and parents understand more about the disease, and to make more informed decisions about vaccinations and to stimulated their interest and involvement in research.

Similar stories

Prestigious award for Oxford professor's diabetes work

A University of Oxford professor has been awarded the 2021 EASD-Novo Nordisk Foundation Prize for Excellence for his decades of effort to understand, prevent and combat type 1 diabetes.

Wellcome accolades for Dr Douglas

Dr Alexander (Sandy) Douglas, an investigator at the Jenner Institute, Nuffield Department of Medicine, has recently received two prestigious Wellcome accolades.

FOCUS4: a flagship trial in colorectal cancer

Professor Tim Maughan (Department of Oncology) outlines the flagship work of the FOCUS4 trials, whose results were presented last weekend at the European Society of Medical Oncology (ESMO) annual meeting

Oxford and Oracle partner to speed identification of COVID-19 variants

The fast spread of the highly infectious Delta variant underscores the need for faster identification of COVID-19 mutations. Uniting governments and medical communities in this challenge, the University of Oxford and Oracle’s Global Pathogen Analysis System (GPAS) is now being used by organizations on nearly every continent. Institutions using the platform include: the University of Montreal Hospital Centre Research Centre, the Institute of Public Health Research of Chile, the Oxford University Clinical Research Unit in Vietnam, the Institute of Clinical Pathology and Medical Research – New South Wales Pathology, and Oxford Nanopore Technologies. GPAS is also now part of the Public Health England New Variant Assessment Platform.

Vaccinated groups at highest risk of Covid-19 hospitalisation and death identified using new QCovid tool

Researchers from the University of Oxford have today reported on findings on the vaccinated people who are at greatest risk from severe Covid-19 leading to hospitalisation or death from 14 days post the second dose vaccination, when substantial immunity should be expected.